Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: A population-based cohort study.

IF 4.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY
Féline O Voss, Guus Fons, Annette H Bruggink, Hans H B Wenzel, Johannes Berkhof, Marc van Beurden, Maaike C G Bleeker
{"title":"Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: A population-based cohort study.","authors":"Féline O Voss, Guus Fons, Annette H Bruggink, Hans H B Wenzel, Johannes Berkhof, Marc van Beurden, Maaike C G Bleeker","doi":"10.1016/j.ygyno.2024.12.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To systematically explore vulvar pathology diagnosed prior to vulvar squamous cell carcinoma (VSCC), as well as the association with tumor characteristics, stage and survival outcome, with the aim of improving vulvar cancer prevention strategies.</p><p><strong>Methods: </strong>VSCC diagnosed between 2005 and 2019 were identified from a population-based cohort provided by the Dutch Nationwide Pathology Databank. Pathology reports were reviewed to identify vulvar pathology diagnosed before primary VSCC. Data on treatment, tumor stage and survival were collected from the Netherlands Cancer Registry. Prior vulvar pathology was correlated to tumor characteristics and stage. Cox's proportional hazards model was used to assess the impact of clinicopathological variables on survival.</p><p><strong>Results: </strong>A total of 1036 VSCC patients were identified, of whom most (73 %) had no prior biopsy-confirmed vulvar pathology. High-grade squamous intraepithelial lesion (HSIL) and differentiated vulvar intraepithelial neoplasia (dVIN) were diagnosed prior to VSCC in only 8 % and 2 % of cancer patients, respectively, while adjacent HSIL and adjacent dVIN were reported in 35 % and 22 % of surgical VSCC resection specimens, respectively. The remaining 17 % had a benign vulvar pathology diagnosis prior to cancer. Patients showed advanced staged tumors in 15 % and 9 % of patients with prior HSIL and dVIN, respectively, as compared to 32 % in patients without prior vulvar pathology (p < 0.001). There was no independent association between prior vulvar pathology and survival outcomes.</p><p><strong>Conclusion: </strong>The vast majority of VSCC patients were not preceded by a pre-malignant lesion or other benign vulvar pathology, although such lesions were frequently identified adjacent to VSCC in resection specimens. Patients without prior vulvar pathology showed more advanced-stage tumors, which may contribute to less favorable outcomes.</p>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"163-170"},"PeriodicalIF":4.5000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ygyno.2024.12.002","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To systematically explore vulvar pathology diagnosed prior to vulvar squamous cell carcinoma (VSCC), as well as the association with tumor characteristics, stage and survival outcome, with the aim of improving vulvar cancer prevention strategies.

Methods: VSCC diagnosed between 2005 and 2019 were identified from a population-based cohort provided by the Dutch Nationwide Pathology Databank. Pathology reports were reviewed to identify vulvar pathology diagnosed before primary VSCC. Data on treatment, tumor stage and survival were collected from the Netherlands Cancer Registry. Prior vulvar pathology was correlated to tumor characteristics and stage. Cox's proportional hazards model was used to assess the impact of clinicopathological variables on survival.

Results: A total of 1036 VSCC patients were identified, of whom most (73 %) had no prior biopsy-confirmed vulvar pathology. High-grade squamous intraepithelial lesion (HSIL) and differentiated vulvar intraepithelial neoplasia (dVIN) were diagnosed prior to VSCC in only 8 % and 2 % of cancer patients, respectively, while adjacent HSIL and adjacent dVIN were reported in 35 % and 22 % of surgical VSCC resection specimens, respectively. The remaining 17 % had a benign vulvar pathology diagnosis prior to cancer. Patients showed advanced staged tumors in 15 % and 9 % of patients with prior HSIL and dVIN, respectively, as compared to 32 % in patients without prior vulvar pathology (p < 0.001). There was no independent association between prior vulvar pathology and survival outcomes.

Conclusion: The vast majority of VSCC patients were not preceded by a pre-malignant lesion or other benign vulvar pathology, although such lesions were frequently identified adjacent to VSCC in resection specimens. Patients without prior vulvar pathology showed more advanced-stage tumors, which may contribute to less favorable outcomes.

外阴鳞状细胞癌前诊断出的外阴病变的患病率和影响:一项基于人群的队列研究。
目的系统探讨外阴鳞状细胞癌(VSCC)之前诊断出的外阴病理学,以及与肿瘤特征、分期和生存结果的关联,以改进外阴癌预防策略:方法:从荷兰全国病理数据库提供的人群队列中识别出2005年至2019年间诊断出的外阴鳞状细胞癌。对病理报告进行审查,以确定在原发性VSCC之前诊断的外阴病理。有关治疗、肿瘤分期和生存期的数据来自荷兰癌症登记处。之前的外阴病理与肿瘤特征和分期相关。采用Cox比例危险模型评估临床病理变量对生存率的影响:结果:共发现了1036例VSCC患者,其中大多数(73%)之前没有活检证实的外阴病理。仅有8%和2%的癌症患者在VSCC发生前确诊为高级别鳞状上皮内病变(HSIL)和分化型外阴上皮内瘤变(dVIN),而在VSCC的手术切除标本中,分别有35%和22%的患者报告了邻近的HSIL和邻近的dVIN。其余17%的患者在罹患癌症前曾有良性外阴病理诊断。在曾有 HSIL 和 dVIN 的患者中,分别有 15% 和 9% 的患者的肿瘤分期为晚期,而在没有外阴病理诊断的患者中,这一比例为 32%(P,结论):绝大多数VSCC患者在患病前没有恶性病变或其他良性外阴病变,尽管在切除标本中经常发现VSCC附近有此类病变。之前没有外阴病变的患者肿瘤分期较晚,这可能是导致预后较差的原因之一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gynecologic oncology
Gynecologic oncology 医学-妇产科学
CiteScore
8.60
自引率
6.40%
发文量
1062
审稿时长
37 days
期刊介绍: Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信